The separation of Ebglyss from Dupixent and Adbry/Adtralza will depend on real-world clinical benefits, patient experience ...

The event will discuss data from emerging OX40/OX40L inhibitors, including Inmagene’s IMG-007 - the only clinical-stage non-depleting anti-OX40 mAb. A live question and answer session will follow the ...

Less frequent dosing could provide Eli Lilly’s Ebglyss room to rival Sanofi and Regeneron’s blockbuster Dupixent.

By blocking IL-22 in keratinocytes, temtokibart normalizes the skin barrier and boosts hydration, suggested a study of gene ...

Eli Lilly's Ebglyss gains FDA approval for atopic dermatitis treatment, poised to rival Dupixent with strong performance in ...

Atopic dermatitis in dogs is an inflammatory condition where a dog's skin shows symptoms of an allergic reaction after the ...

As a student, Mr David Low* made every effort to take part in physical education lessons, but eczema flare-ups often kept him ...

With its recent US Food and Drug Administration (FDA) approval, Eli Lilly’s Ebglyss (lebrikizumab) adds a new competitor to ...

Global skin rash treatment market is estimated to be valued at USD 3.67 Bn in 2024 and is expected to reach USD 5.70 Bn by ...

Discover research presented at EADV 2024 highlighting the significant impact of atopic dermatitis on psychological and social ...

Ebglyss' approval highlights the opportunity that exists in the AD space, and may have potential advantages in efficacy and ...

Topical delgocitinib appears more effective than oral alitretinoin and is comparable to dupilumab for treating types of hand eczema, according to two separate studies.